Trials / Recruiting
RecruitingNCT05651828
Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare how well tolerated and effective four different dosing schedules (two personalized, intermittent dosing schedules as compared to a fixed intermittent and continuous dosing regimen) work in people with advanced basal cell carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vismodegib 150 MG Oral Capsule | Vismodegib is a hedgehog signalling pathway target agent. Participants will self-administer the standard 150 mg dose by mouth. |
Timeline
- Start date
- 2023-03-23
- Primary completion
- 2028-12-01
- Completion
- 2029-12-01
- First posted
- 2022-12-15
- Last updated
- 2026-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05651828. Inclusion in this directory is not an endorsement.